Success Metrics

Clinical Success Rate
87.2%

Based on 313 completed trials

Completion Rate
87%(313/359)
Active Trials
27(5%)
Results Posted
40%(125 trials)
Terminated
46(8%)

Phase Distribution

Ph not_applicable
67
12%
Ph phase_2
167
31%
Ph phase_3
115
21%
Ph early_phase_1
17
3%
Ph phase_1
69
13%
Ph phase_4
109
20%

Phase Distribution

86

Early Stage

167

Mid Stage

224

Late Stage

Phase Distribution544 total trials
Early Phase 1First-in-human
17(3.1%)
Phase 1Safety & dosage
69(12.7%)
Phase 2Efficacy & side effects
167(30.7%)
Phase 3Large-scale testing
115(21.1%)
Phase 4Post-market surveillance
109(20.0%)
N/ANon-phased studies
67(12.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.3%

313 of 390 finished

Non-Completion Rate

19.7%

77 ended early

Currently Active

27

trials recruiting

Total Trials

546

all time

Status Distribution
Active(32)
Completed(313)
Terminated(77)
Other(124)

Detailed Status

Completed313
unknown121
Terminated46
Withdrawn31
Recruiting19
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
546
Active
27
Success Rate
87.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 117 (3.1%)
Phase 169 (12.7%)
Phase 2167 (30.7%)
Phase 3115 (21.1%)
Phase 4109 (20.0%)
N/A67 (12.3%)

Trials by Status

suspended31%
terminated468%
recruiting193%
unknown12122%
withdrawn316%
not_yet_recruiting31%
enrolling_by_invitation20%
active_not_recruiting81%
completed31357%

Recent Activity

Clinical Trials (546)

Showing 20 of 546 trialsScroll for more
NCT03029429Phase 2

Theophylline Treatment for Pseudohypoparathyroidism

Active Not Recruiting
NCT03783429Phase 4

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

Completed
NCT01682083Phase 3

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Completed
NCT07499700Phase 2

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Recruiting
NCT03574909Phase 3

IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes

Completed
NCT04325958Not Applicable

Age Differences in the Effects of Cannabis on Simulated Driving

Recruiting
NCT04379635Phase 3

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT04373473Phase 2

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

Recruiting
NCT03269058Phase 4

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

Completed
NCT03552705Phase 2

The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients

Recruiting
NCT04374799Phase 3

Heparin vs Placebo for Cardiac Catheterization

Recruiting
NCT04353778Phase 1

Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

Recruiting
NCT04169997Phase 3

A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Active Not Recruiting
NCT04237103Phase 2

Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Completed
NCT04251819Phase 2

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

Terminated
NCT04192435Phase 4

Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery

Completed
NCT03744975Phase 2

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Completed
NCT04138706Phase 3

Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

Completed
NCT03935295Phase 4

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

Recruiting
NCT04063540Phase 2

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
546